<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04993430</url>
  </required_header>
  <id_info>
    <org_study_id>HRS8807-I-101</org_study_id>
    <nct_id>NCT04993430</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer</brief_title>
  <official_title>A Phase 1, Single Arm, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Hengrui Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Hengrui Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to assess safety and tolerability of HRS8807 monotherapy and in combination with&#xD;
      SHR6390 in subjects with metastatic or locally advanced breast cancer in order to estimate&#xD;
      the Dose-Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and select the Recommended&#xD;
      Phase 2 Dose (RP2D).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>HRS8807 monotherapy and in combination with SHR6390</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>Change From Baseline at 28 days</time_frame>
    <description>Maximum Tolerated Dose (MTD) of HRS8807 monotherapy and in combination with SHR6390</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D</measure>
    <time_frame>Change From Baseline at 28 days</time_frame>
    <description>select the Recommended Phase 2 Dose (RP2D) of HRS8807 monotherapy and in combination with SHR6390</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AE) and serious AE (SAE)</measure>
    <time_frame>Up to 30 days after end of treatment</time_frame>
    <description>AEs and SAEs as characterized by frequency and severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE version 5.0]).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of HRS8807 and the major metabolite after single dose of HRS8807</measure>
    <time_frame>Day 1, Day 2, Day 3 of single dose (3 days before Cycle1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of HRS8807 and the major metabolite after single dose of HRS8807</measure>
    <time_frame>Day 1, Day 2, Day 3 of single dose (3 days before Cycle1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t of HRS8807 and the major metabolite after single dose of HRS8807</measure>
    <time_frame>Day 1, Day 2, Day 3 of single dose (3 days before Cycle1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ of HRS8807 and the major metabolite after single dose of HRS8807</measure>
    <time_frame>Day 1, Day 2, Day 3 of single dose (3 days before Cycle1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of HRS8807 and the major metabolite after single dose of HRS8807</measure>
    <time_frame>Day 1, Day 2, Day 3 of single dose (3 days before Cycle1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F of HRS8807 and the major metabolite after single dose of HRS8807</measure>
    <time_frame>Day 1, Day 2, Day 3 of single dose (3 days before Cycle1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of HRS8807 and the major metabolite after single dose of HRS8807</measure>
    <time_frame>Day 1, Day 2, Day 3 of single dose (3 days before Cycle1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of HRS8807 and the major metabolite after multiple dose administration of HRS8807</measure>
    <time_frame>Cycle 1 Day 14, Day 15, each cycle is 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss of HRS8807 and the major metabolite after multiple dose administration of HRS8807</measure>
    <time_frame>Cycle 1 Day 14, Day 15, each cycle is 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss of HRS8807 and the major metabolite after multiple dose administration of HRS8807</measure>
    <time_frame>Cycle 1 Day 14, Day 15, each cycle is 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rac of HRS8807 and the major metabolite after multiple dose administration of HRS8807</measure>
    <time_frame>Cycle 1 Day 14, Day 15, each cycle is 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCss of HRS8807 and the major metabolite after multiple dose administration of HRS8807</measure>
    <time_frame>Cycle 1 Day 14, Day 15, each cycle is 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of HRS8807, the major metabolite and SHR6390 after single dose administration of HRS8807 and SHR6390</measure>
    <time_frame>Cycle 1 Day 1, Day 2, each cycle is 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of HRS8807, the major metabolite and SHR6390 after single dose administration of HRS8807 and SHR6390</measure>
    <time_frame>Cycle 1 Day 1, Day 2, each cycle is 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t of HRS8807, the major metabolite and SHR6390 after single dose administration of HRS8807 and SHR6390</measure>
    <time_frame>Cycle 1 Day 1, Day 2, each cycle is 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of HRS8807, the major metabolite and SHR6390 after multiple dose administration of HRS8807 and SHR6390</measure>
    <time_frame>Cycle 1 Day 14, Day 15, each cycle is 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss of HRS8807, the major metabolite and SHR6390 after multiple dose administration of HRS8807 and SHR6390</measure>
    <time_frame>Cycle 1 Day 14, Day 15, each cycle is 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss of HRS8807, the major metabolite and SHR6390 after multiple dose administration of HRS8807 and SHR6390</measure>
    <time_frame>Cycle 1 Day 14, Day 15, each cycle is 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCss of HRS8807, the major metabolite and SHR6390 after multiple dose administration of HRS8807 and SHR6390</measure>
    <time_frame>Cycle 1 Day 14, Day 15, each cycle is 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rac of HRS8807, the major metabolite and SHR6390 after multiple dose administration of HRS8807 and SHR6390</measure>
    <time_frame>Cycle 1 Day 14, Day 15, each cycle is 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>baseline to the date of first documentation of progression, assessed approximately up to 6 months after the last entered participant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>baseline to the date of first documentation of progression, assessed approximately up to 6 months after the last entered participant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>baseline to the date of first documentation of progression, assessed approximately up to 6 months after the last entered participant</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>ER-Positive, HER2-Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HRS8807 monotherapy dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HRS8807 monotherapy dose expansion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HRS8807 in combination with SHR6390 dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HRS8807 in combination with SHR6390 dose expansion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HRS8807</intervention_name>
    <description>HRS8807 monotherapy</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HRS8807</intervention_name>
    <description>HRS8807 monotherapy</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HRS8807、SHR6390</intervention_name>
    <description>HRS8807 in combination with SHR6390</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HRS8807、SHR6390</intervention_name>
    <description>HRS8807 in combination with SHR6390</description>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological diagnosis of metastatic or locally advanced breast cancer; Histologically&#xD;
             proven diagnosis of ER-positive, HER2-negative;&#xD;
&#xD;
          2. At least 1 line of endocrine therapy in the metastatic or advanced setting that had&#xD;
             progressed or intolerance; ≤ 2 lines of chemotherapy for metastatic or advanced&#xD;
             disease;&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1;&#xD;
&#xD;
          4. Expected survival of more than 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. All patients in monotherapy and or in combination wih phase who are known allergic to&#xD;
             HRS8807 or SHR6390 ingredient;&#xD;
&#xD;
          2. Presence of symptomatic metastatic visceral disease ;&#xD;
&#xD;
          3. Patients with known active brain metastases;&#xD;
&#xD;
          4. Clinically serious cardiovascular disease;&#xD;
&#xD;
          5. Abnormal electrocardiographic (ECG) with clinical significancy by investigator&#xD;
             judgement;&#xD;
&#xD;
          6. Abnormal thyroid function laboratory results;&#xD;
&#xD;
          7. Active infection or unexplained fever &gt;38.5℃ during screening period or on the day of&#xD;
             the first dose.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wenjie Xin</last_name>
    <phone>+0518-81220121</phone>
    <email>Wenjie.xin@hengrui.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiong Wu, Doctor</last_name>
      <phone>021-64175590</phone>
      <email>wujiong1122@vip.sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Jian Zhang</last_name>
      <phone>021-64175590</phone>
      <email>syner2000@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

